Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 4/20 | 0.32 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3508921 | 0.92 | BRAF (0.38) | BRAFABL1BCR | |
| SCHEMBL3509949 | 0.86 | BRAF (0.35) | BRAFMAP4K4ABL1BCRTMPRSS15 | |
| SCHEMBL1258993 | 0.83 | BRAF (0.57) | BRAFABL1MAPK14 | |
| SCHEMBL3511679 | 0.82 | NPC1 (0.38) | BRAFMAP4K4 | |
| SCHEMBL3512291 | 0.82 | BRAF (0.33) | BRAFABL1BCR | |
| SCHEMBL2455537 | 0.80 | BRAF (0.43) | BRAFMAP4K4ABL1BCR | |
| SCHEMBL1259549 | 0.79 | MEN1 (0.48) | MET | |
| SCHEMBL14949680 | 0.79 | MET (0.44) | MAP4K4ABL1BCRMET | |
| SCHEMBL3512217 | 0.78 | BRAF (0.46) | BRAF | |
| SCHEMBL12892609 | 0.78 | BRAF (0.49) | BRAFMAP4K4ABL1BCRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | BRAF 84/4885MAP4K4 30/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.